Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Journal of the National Cancer Institute
|
February 5, 2019
Response to Katona et al
Mok Oh, Ali McBride, Seongseok Yun, et al.
Journal of Medical Economics
|
August 27, 2020
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing
Nimer S Alkhatib, Ali McBride, Sandipan Bhattacharjee, et al.
Journal of the National Cancer Institute
|
August 20, 2019
Response to Yang, Shi, Wang et al
Mok Oh, Ali McBride, Seongseok Yun, et al.
Journal of the National Cancer Institute
|
November 1, 2018
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Mok Oh, Ali McBride, Seongseok Yun, et al.
Pharmacoeconomics
|
June 28, 2018
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
Mahdi Gharaibeh, Ali McBride, David S Alberts, et al.
Pharmacoeconomics
|
July 8, 2018
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
Mahdi Gharaibeh, Ali McBride, David S Alberts, et al.
BMJ Open Quality
|
October 12, 2018
Systematic review and meta-analysis of community pharmacy error rates in the USA: 1993-2015
Patrick J Campbell, Mira Patel, Jennifer R Martin, et al.
Research in Social & Administrative Pharmacy : RSAP
|
May 19, 2021
Association of low-income subsidy, medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries
Chanadda Chinthammit, Sandipan Bhattacharjee, Wei-Hsuan Lo-Ciganic, et al.
Journal of Managed Care & Specialty Pharmacy
|
September 30, 2020
Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region
Chanadda Chinthammit, Sandipan Bhattacharjee, David R Axon, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
July 26, 2020
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure
Nimer Alkhatib, Nancy K Sweitzer, Christopher S Lee, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Journal of the National Cancer Institute
|
February 5, 2019
Response to Katona et al
Mok Oh, Ali McBride, Seongseok Yun, et al.
Journal of Medical Economics
|
August 27, 2020
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing
Nimer S Alkhatib, Ali McBride, Sandipan Bhattacharjee, et al.
Journal of the National Cancer Institute
|
August 20, 2019
Response to Yang, Shi, Wang et al
Mok Oh, Ali McBride, Seongseok Yun, et al.
Journal of the National Cancer Institute
|
November 1, 2018
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Mok Oh, Ali McBride, Seongseok Yun, et al.
Pharmacoeconomics
|
June 28, 2018
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
Mahdi Gharaibeh, Ali McBride, David S Alberts, et al.
Pharmacoeconomics
|
July 8, 2018
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
Mahdi Gharaibeh, Ali McBride, David S Alberts, et al.
BMJ Open Quality
|
October 12, 2018
Systematic review and meta-analysis of community pharmacy error rates in the USA: 1993-2015
Patrick J Campbell, Mira Patel, Jennifer R Martin, et al.
Research in Social & Administrative Pharmacy : RSAP
|
May 19, 2021
Association of low-income subsidy, medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries
Chanadda Chinthammit, Sandipan Bhattacharjee, Wei-Hsuan Lo-Ciganic, et al.
Journal of Managed Care & Specialty Pharmacy
|
September 30, 2020
Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region
Chanadda Chinthammit, Sandipan Bhattacharjee, David R Axon, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
July 26, 2020
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure
Nimer Alkhatib, Nancy K Sweitzer, Christopher S Lee, et al.
Page
of 5